Core Viewpoint - The investor call and webcast are focused on presenting the results of the ProstACT Global Phase III study, specifically the Part 1 safety and dosimetry lead-in [1]. Group 1: Company Overview - Kyahn Williamson serves as the Senior Vice President of Corporate Communications & Investor Relations at Telix [1]. - Dr. Christian Behrenbruch, the Managing Director and Group CEO, will provide introductory remarks during the presentation [2]. Group 2: Study Presentation - Dr. David Cade, the Chief Medical Officer, is responsible for presenting the data from the study [2]. - Dr. Pedro Barata, a Medical Oncologist and Associate Professor at Case Western Reserve University, will share case studies and insights as a guest speaker [2].